Organon & Co (OGN) is a Healthcare · Drug Manufacturers - General company listed on NYSE. Price $13.69 (+0.15%), Market cap $3.50B, P/E ratio 14.33, 52-week low–high $5.70 ~ $13.41.
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine
Financial statements, price targets, institutional (13F) holdings and related news for Organon & Co are updated in real time on BlackAll Trade.
Organon & Co trades at $13.69 (+0.15%). Real-time quotes and charts are available on BlackAll Trade.
Organon & Co has a market cap of about $3.50B. Its P/E ratio is 14.33.
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin Americ